Literature DB >> 28585877

Future of Automated Insulin Delivery Systems.

Jessica R Castle1, J Hans DeVries2, Boris Kovatchev3.   

Abstract

Advances in continuous glucose monitoring (CGM) have brought on a paradigm shift in the management of type 1 diabetes. These advances have enabled the automation of insulin delivery, where an algorithm determines the insulin delivery rate in response to the CGM values. There are multiple automated insulin delivery (AID) systems in development. A system that automates basal insulin delivery has already received Food and Drug Administration approval, and more systems are likely to follow. As the field of AID matures, future systems may incorporate additional hormones and/or multiple inputs, such as activity level. All AID systems are impacted by CGM accuracy and future CGM devices must be shown to be sufficiently accurate to be safely incorporated into AID. In this article, we summarize recent achievements in AID development, with a special emphasis on CGM sensor performance, and discuss the future of AID systems from the point of view of their input-output characteristics, form factor, and adaptability.

Entities:  

Keywords:  Artificial pancreas; Continuous glucose monitoring; Type 1 diabetes

Mesh:

Year:  2017        PMID: 28585877      PMCID: PMC5467099          DOI: 10.1089/dia.2017.0012

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  65 in total

1.  Glucose requirements to maintain euglycemia after moderate-intensity afternoon exercise in adolescents with type 1 diabetes are increased in a biphasic manner.

Authors:  Sarah K McMahon; Luis D Ferreira; Nirubasini Ratnam; Raymond J Davey; Leanne M Youngs; Elizabeth A Davis; Paul A Fournier; Timothy W Jones
Journal:  J Clin Endocrinol Metab       Date:  2006-11-21       Impact factor: 5.958

2.  In silico optimization of basal insulin infusion rate during exercise: implication for artificial pancreas.

Authors:  Michele Schiavon; Chiara Dalla Man; Yogish C Kudva; Ananda Basu; Claudio Cobelli
Journal:  J Diabetes Sci Technol       Date:  2013-11-01

3.  Technical aspects of the Parkes error grid.

Authors:  Andreas Pfützner; David C Klonoff; Scott Pardo; Joan L Parkes
Journal:  J Diabetes Sci Technol       Date:  2013-09-01

4.  Hypoglycemia Reduction and Accuracy of Continuous Glucose Monitoring.

Authors:  Boris P Kovatchev
Journal:  Diabetes Technol Ther       Date:  2015-05-15       Impact factor: 6.118

5.  Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.

Authors:  Ahmad Haidar; Laurent Legault; Virginie Messier; Tina Maria Mitre; Catherine Leroux; Rémi Rabasa-Lhoret
Journal:  Lancet Diabetes Endocrinol       Date:  2014-11-27       Impact factor: 32.069

6.  Variability of Insulin Requirements Over 12 Weeks of Closed-Loop Insulin Delivery in Adults With Type 1 Diabetes.

Authors:  Yue Ruan; Hood Thabit; Lalantha Leelarathna; Sara Hartnell; Malgorzata E Willinska; Sibylle Dellweg; Carsten Benesch; Julia K Mader; Manuel Holzer; Harald Kojzar; Mark L Evans; Thomas R Pieber; Sabine Arnolds; Roman Hovorka
Journal:  Diabetes Care       Date:  2016-03-10       Impact factor: 19.112

7.  Basement Membrane-Based Glucose Sensor Coatings Enhance Continuous Glucose Monitoring in Vivo.

Authors:  Ulrike Klueh; Yi Qiao; Caroline Czajkowski; Izabela Ludzinska; Omar Antar; Donald L Kreutzer
Journal:  J Diabetes Sci Technol       Date:  2015-08-25

8.  Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes.

Authors:  Stuart A Weinzimer; Jennifer L Sherr; Eda Cengiz; Grace Kim; Jessica L Ruiz; Lori Carria; Gayane Voskanyan; Anirban Roy; William V Tamborlane
Journal:  Diabetes Care       Date:  2012-07-18       Impact factor: 19.112

9.  Accuracy of Continuous Glucose Monitoring During Three Closed-Loop Home Studies Under Free-Living Conditions.

Authors:  Hood Thabit; Lalantha Leelarathna; Malgorzata E Wilinska; Daniella Elleri; Janet M Allen; Alexandra Lubina-Solomon; Emma Walkinshaw; Marietta Stadler; Pratik Choudhary; Julia K Mader; Sibylle Dellweg; Carsten Benesch; Thomas R Pieber; Sabine Arnolds; Simon R Heller; Stephanie A Amiel; David Dunger; Mark L Evans; Roman Hovorka
Journal:  Diabetes Technol Ther       Date:  2015-08-04       Impact factor: 6.118

10.  Performance and safety of an integrated bihormonal artificial pancreas for fully automated glucose control at home.

Authors:  H Blauw; A C van Bon; R Koops; J H DeVries
Journal:  Diabetes Obes Metab       Date:  2016-04-25       Impact factor: 6.577

View more
  5 in total

1.  The Future of Continuous Glucose Monitoring.

Authors:  Satish K Garg; Halis K Akturk
Journal:  Diabetes Technol Ther       Date:  2017-06       Impact factor: 6.118

2.  Design and Clinical Evaluation of the Interoperable Artificial Pancreas System (iAPS) Smartphone App: Interoperable Components with Modular Design for Progressive Artificial Pancreas Research and Development.

Authors:  Sunil Deshpande; Jordan E Pinsker; Stamatina Zavitsanou; Dawei Shi; Randy Tompot; Mei Mei Church; Camille Andre; Francis J Doyle; Eyal Dassau
Journal:  Diabetes Technol Ther       Date:  2018-12-14       Impact factor: 6.118

3.  Continuous glucose monitoring and glycemic control among youth with type 1 diabetes: International comparison from the T1D Exchange and DPV Initiative.

Authors:  Daniel J DeSalvo; Kellee M Miller; Julia M Hermann; David M Maahs; Sabine E Hofer; Mark A Clements; Eggert Lilienthal; Jennifer L Sherr; Martin Tauschmann; Reinhard W Holl
Journal:  Pediatr Diabetes       Date:  2018-07-01       Impact factor: 4.866

4.  Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes.

Authors:  Gregory P Forlenza; Orit Pinhas-Hamiel; David R Liljenquist; Dorothy I Shulman; Timothy S Bailey; Bruce W Bode; Michael A Wood; Bruce A Buckingham; Kevin B Kaiserman; John Shin; Suiying Huang; Scott W Lee; Francine R Kaufman
Journal:  Diabetes Technol Ther       Date:  2018-12-26       Impact factor: 6.118

5.  Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus.

Authors:  Ulrike Hövelmann; Minna Braendholt Olsen; Ulrik Mouritzen; Daniela Lamers; Birgit Kronshage; Tim Heise
Journal:  Diabetes Obes Metab       Date:  2018-11-28       Impact factor: 6.577

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.